New kidney disease drug enters first human testing
NCT ID NCT06982729
Summary
This is the first human study to test the safety and early effects of a new drug called YK012 for primary membranous nephropathy, a kidney disease where the body's immune system attacks the kidneys. The trial will enroll 72 adults with this condition to find the safest dose and see how the body processes the drug. Researchers will also look for early signs that the drug might help reduce kidney damage and protein loss in urine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.